Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates
Authors:
- 1 December 1989
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 27 (12) , 2799-2804
Abstract
In a phase 1 study to evaluate human-rhesus rotavirus reassortant vaccines, 116 infants 1 to 5 months of age received one of the following five preparations: the serotype 1 reassortant, the serotype 2 reassortant, rhesus rotavirus (serotype 3), a bivalent preparation (serotypes 1 and 3), or a placebo. Seroresponses to the different vaccines were measured by plaque reduction neutralization assay (PRNA); rotavirus-specific immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays (ELISAs); and complement fixation (CF). The seroresponse rate, calculated by using a fourfold or greater antibody rise by any assay, was similar in the four vaccine groups (83 to 96%). When the data from all the vaccinees were pooled, IgA ELISA, IgG ELISA, and PRNA were comparable in detecting seroresponses (67, 62, and 70%, respectively) and more efficient than IgM ELISA (53%) and CF (44%). When the vaccinees were analyzed by age, the overall seroresponse rates were the same for infants 1 to 2 and 3 to 5 months old (90%). The IgA ELISA and PRNA were the most efficient for detecting antibody rises in both age groups. IgG ELISA was among the least efficient methods for detecting antibody rises in the younger age group but among the most efficient in the older age group (44 versus 78%). CF was among the least efficient methods in both age groups but was significantly better in the older age group than in the younger age group (54 versus 21%). Our findings show that ELISA, in particular rotavirus-specific IgA ELISA, is a sensitive indicator of vaccine takes in 1- to 5 month-old infants, the target population for vaccination. ELISA should also be very useful in demonstrating natural rotavirus infections in field studies in which a stool specimen from a diarrheal episode is not always available. The ELISA has the advantages of being easier and quicker and requiring less serum than PRNA, but it does not give serotype-specific information about the immune response.Keywords
This publication has 33 references indexed in Scilit:
- Human-Rhesus Reassortant Rotavirus Vaccines: Safety and Immunogenicity in Adults, Infants, and ChildrenThe Journal of Infectious Diseases, 1988
- Serum and Salivary Antibodies as Indicators of Rotavirus Infection in NeonatesThe Journal of Infectious Diseases, 1988
- Reactogenicity and antigenicity of rhesus rotavirus vaccine (MMU-18006) in newborn infants in VenezuelaThe Pediatric Infectious Disease Journal, 1988
- Protective effect of preexisting rotavirus‐specific immunoglobulin A against naturally acquired rotavirus infection in childrenJournal of Medical Virology, 1987
- Detection by ELISA of immunoglobulin G subclass‐specific antibody responses in rotavirus infections in childrenJournal of Medical Virology, 1986
- Safety, infectivity, transmissibility and immunogenicity of rhesus rotavirus vaccine (MMU 18006) in infantsThe Pediatric Infectious Disease Journal, 1986
- Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemicThe Journal of Pediatrics, 1985
- Intestinal and Serum Immune Response to a Naturally Acquired Rotavirus Gastroenteritis in ChildrenJournal of Pediatric Gastroenterology and Nutrition, 1985
- Development of serum and intestinal antibody response to rotavirus after naturally acquired rotavirus infection in manJournal of Medical Virology, 1981
- Solid-phase radioimmunoassay of IgA, IgG, and IgM antibodies to human rotavirusJournal of Medical Virology, 1979